Intraperitoneal FS-NH2 administration also inhibited pain-related behaviors in pancreatic tumor-bearing mice, suggesting that PAR-2 might be an effective therapeutic target for reducing pancreatic cancer pain. This evidence concerns the gene F2RL1 and familial pancreatic carcinoma.